Novonesis (Novozymes) A/S Total Liabilities

Latest as of March 2026: Dkr5.60 Billion DKK ≈ $876.71 Million USD

Novonesis (Novozymes) A/S total liabilities. Based on the latest financial reports, Novonesis (Novozymes) A/S (NSIS-B) has total liabilities worth Dkr5.60 Billion DKK (≈ $876.71 Million USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See Novonesis (Novozymes) A/S defensive liquidity buffer to measure how many days the company can operate on defensive assets alone.

Total Liabilities of Novonesis (Novozymes) A/S (2002–2025)

Total liabilities of Novonesis (Novozymes) A/S from 2002 to 2025. This chart illustrates how Novonesis (Novozymes) A/S's total liabilities have evolved over time, based on quarterly financial data. Check Novonesis (Novozymes) A/S (NSIS-B) liquid assets ratio to evaluate the company's liquid asset resilience ratio.

Novonesis (Novozymes) A/S Competitors by Total Liabilities

The table below lists competitors of Novonesis (Novozymes) A/S ranked by their total liabilities.

Company Country Total Liabilities
Transurban Group
AU:TCL
Australia AU$25.55 Billion
Jabil Circuit Inc
NYSE:JBL
USA $22.49 Billion
Ameren Corp
NYSE:AEE
USA $37.40 Billion
Fortis Inc
TO:FTS
Canada CA$51.30 Billion
Alcon AG
SW:ALC
Switzerland CHF9.51 Billion
Prudential plc
F:PRU2
Germany €203.06 Billion
Banco Bradesco S.A
F:BREC
Germany €2.29 Trillion
Pembina Pipeline Corp
TO:PPL
Canada CA$19.27 Billion

Liability Composition Analysis (2002–2025)

This chart breaks down Novonesis (Novozymes) A/S's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Novonesis (Novozymes) A/S balance sheet assets.

Liquidity & Leverage Metrics

Novonesis (Novozymes) A/S Total Liabilities Ratios Explained

Novonesis (Novozymes) A/S total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.

Metric Value Description
Current Ratio 1.67 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 0.51 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.34 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Novonesis (Novozymes) A/S's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Novonesis (Novozymes) A/S (2002–2025)

The table below shows the annual total liabilities of Novonesis (Novozymes) A/S from 2002 to 2025.

Year Total Liabilities Change
2025-12-31 Dkr5.49 Billion
≈ $859.56 Million
+36.68%
2024-12-31 Dkr4.02 Billion
≈ $628.90 Million
-71.37%
2023-12-31 Dkr14.04 Billion
≈ $2.20 Billion
+2.07%
2022-12-31 Dkr13.76 Billion
≈ $2.15 Billion
+9.51%
2021-12-31 Dkr12.56 Billion
≈ $1.97 Billion
+35.56%
2020-12-31 Dkr9.27 Billion
≈ $1.45 Billion
+3.45%
2019-12-31 Dkr8.96 Billion
≈ $1.40 Billion
+8.45%
2018-12-31 Dkr8.26 Billion
≈ $1.29 Billion
+16.23%
2017-12-31 Dkr7.11 Billion
≈ $1.11 Billion
+2.78%
2016-12-31 Dkr6.91 Billion
≈ $1.08 Billion
+11.55%
2015-12-31 Dkr6.20 Billion
≈ $969.72 Million
-13.27%
2014-12-31 Dkr7.15 Billion
≈ $1.12 Billion
+31.36%
2013-12-31 Dkr5.44 Billion
≈ $851.13 Million
-1.89%
2012-12-31 Dkr5.54 Billion
≈ $867.56 Million
+10.50%
2011-12-31 Dkr5.02 Billion
≈ $785.10 Million
+5.49%
2010-12-31 Dkr4.76 Billion
≈ $744.27 Million
-5.60%
2009-12-31 Dkr5.04 Billion
≈ $788.39 Million
-7.52%
2008-12-31 Dkr5.45 Billion
≈ $852.54 Million
+4.71%
2007-12-31 Dkr5.20 Billion
≈ $814.20 Million
+13.82%
2006-12-31 Dkr4.57 Billion
≈ $715.32 Million
+30.07%
2005-12-31 Dkr3.52 Billion
≈ $549.95 Million
+8.42%
2004-12-31 Dkr3.24 Billion
≈ $507.23 Million
-6.25%
2003-12-31 Dkr3.46 Billion
≈ $541.03 Million
-15.70%
2002-12-31 Dkr4.10 Billion
≈ $641.79 Million
--

About Novonesis (Novozymes) A/S

CO:NSIS-B Denmark Specialty Chemicals
Market Cap
$30.03 Billion
Dkr191.93 Billion DKK
Market Cap Rank
#885 Global
#6 in Denmark
Share Price
Dkr465.30
Change (1 day)
+0.02%
52-Week Range
Dkr342.00 - Dkr481.50
All Time High
Dkr508.57
About

Novozymes A/S produces and sells industrial enzymes, functional proteins, and microorganisms in Denmark, rest of Europe, North America, the Asia Pacific, the Middle East, Africa, and Latin America. It provides biosolutions for the food and beverage industry, such as dairy, baking, beverage, meat, plant-based, functional, and other foods, as well as precision protein and early lie nutrition. The c… Read more